PMN
ProMIS Neurosciences, Inc.
Biotechnology
Market Cap$68M
5Y Perf.-95.7%
Build Your Comparison
Side-by-side financial analysisPMN
ARVN
Try popular comparisons:
Stock Comparison
PMN vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$489M
5Y Perf.-77.4%
PMN vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  PMN |  ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $68M | $489M |
| Revenue (TTM) | $0.00 | $89M |
| Net Income (TTM) | $-41M | $-221M |
| Gross Margin | — | 97.4% |
| Operating Margin | — | -279.3% |
| Total Debt | $0.00 | $9M |
| Cash & Equiv. | $6M | $143M |
PMN vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PMN
ARVN
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| ProMIS Neuroscience… (PMN) | 100 | 4.3 | -95.7% |
| Arvinas, Inc. (ARVN) | 100 | 22.6 | -77.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PMN vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARVN leads in 2 of 4 categories, making it the strongest pick for recent price momentum and sentiment and operational efficiency and capital deployment. ProMIS Neurosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ARVN emerged as the overall leader. Track its performance:
PMN
ProMIS Neurosciences, Inc.
The Income Pick
PMN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.11
- Lower volatility, beta 1.11, current ratio 0.88x
- Beta 1.11, current ratio 0.88x
Best for: income & stability and sleep-well-at-night
ARVN
Arvinas, Inc.
The Growth Play
ARVN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
- -52.8% 10Y total return vs PMN's -91.4%
- +0.1% vs PMN's -20.4%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  PMN | Beta 1.11 vs ARVN's 1.14 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  ARVN | +0.1% vs PMN's -20.4% |
| Efficiency (ROA) | ARVN | -28.4% ROA vs PMN's -151.0% |
PMN vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PMN vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARVNLAGGINGPMN
PMNProMIS Neurosciences,…
1leads
ARVNArvinas, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs PMNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PMN1/1
Valuation MetricsMultiples, price ratios, and targets
ARVN1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ARVN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PMN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARVN and PMN operate at a comparable scale, with $89M and $0 in trailing revenue.
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $89M |
| EBITDAEarnings before interest/tax | -$41M | -$245M |
| Net IncomeAfter-tax profit | -$41M | -$221M |
| Free Cash FlowCash after capex | -$35M | -$257M |
| Gross MarginGross profit ÷ Revenue | — | +97.4% |
| Operating MarginEBIT ÷ Revenue | — | -2.8% |
| Net MarginNet income ÷ Revenue | — | -2.5% |
| FCF MarginFCF ÷ Revenue | — | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -91.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +76.0% | -178.9% |
PMN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ARVN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $68M | $489M |
| Enterprise ValueMkt cap + debt − cash | $61M | $355M |
| Trailing P/EPrice ÷ TTM EPS | -0.46x | -5.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.86x |
| Price / BookPrice ÷ Book value/share | — | 1.13x |
| Price / FCFMarket cap ÷ FCF | — | — |
ARVN leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ARVN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ARVN delivers a -44.4% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-2 for PMN. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs PMN's 0/9, reflecting mixed financial health.
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -44.4% |
| ROA (TTM)Return on assets | -151.0% | -28.4% |
| ROICReturn on invested capital | — | -22.4% |
| ROCEReturn on capital employed | -5.2% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 4 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$6M | -$134M |
| Cash & Equiv.Liquid assets | $6M | $143M |
| Total DebtShort + long-term debt | $0 | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ARVN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ARVN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARVN five years ago would be worth $900 today (with dividends reinvested), compared to $363 for PMN. Over the past 12 months, ARVN leads with a +0.1% total return vs PMN's -20.4%. The 3-year compound annual growth rate (CAGR) favors ARVN at -35.9% vs PMN's -56.0% — a key indicator of consistent wealth creation.
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +45.0% | -33.9% |
| 1-Year ReturnPast 12 months | -20.4% | +0.1% |
| 3-Year ReturnCumulative with dividends | -91.5% | -73.7% |
| 5-Year ReturnCumulative with dividends | -96.4% | -91.0% |
| 10-Year ReturnCumulative with dividends | -91.4% | -52.8% |
| CAGR (3Y)Annualised 3-year return | -56.0% | -35.9% |
ARVN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PMN and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
PMN is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than ARVN's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARVN currently trades 52.2% from its 52-week high vs PMN's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.14x |
| 52-Week HighHighest price in past year | $39.75 | $14.51 |
| 52-Week LowLowest price in past year | $6.27 | $6.06 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +52.2% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 24.1 |
| Avg Volume (50D)Average daily shares traded | 34K | 794K |
Evenly matched — PMN and ARVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PMN as "Buy" and ARVN as "Buy". Consensus price targets imply 94.6% upside for ARVN (target: $15) vs 73.9% for PMN (target: $18).
| Metric | PMNProMIS Neuroscien… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $14.75 |
| # AnalystsCovering analysts | 2 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +18.8% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARVN leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). PMN leads in 1 (Income & Cash Flow). 1 tied.
Best OverallArvinas, Inc. (ARVN)Leads 3 of 6 categories
Loading custom metrics...
PMN vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PMN or ARVN a better buy right now?
Analysts rate ProMIS Neurosciences, Inc.
(PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PMN or ARVN?
Over the past 5 years, Arvinas, Inc.
(ARVN) delivered a total return of -91. 0%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: ARVN returned -52. 8% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PMN or ARVN?
By beta (market sensitivity over 5 years), ProMIS Neurosciences, Inc.
(PMN) is the lower-risk stock at 1. 11β versus Arvinas, Inc. 's 1. 14β — meaning ARVN is approximately 3% more volatile than PMN relative to the S&P 500.
04Which is growing faster — PMN or ARVN?
On earnings-per-share growth, the picture is similar: Arvinas, Inc.
grew EPS 53. 8% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PMN or ARVN?
ProMIS Neurosciences, Inc.
(PMN) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PMN leads at 0. 0% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PMN or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PMN or ARVN better for a retirement portfolio?
For long-horizon retirement investors, ProMIS Neurosciences, Inc.
(PMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Both have compounded well over 10 years (PMN: -91. 4%, ARVN: -52. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PMN and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.